DOP2020000031A - Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento - Google Patents

Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento

Info

Publication number
DOP2020000031A
DOP2020000031A DO2020000031A DO2020000031A DOP2020000031A DO P2020000031 A DOP2020000031 A DO P2020000031A DO 2020000031 A DO2020000031 A DO 2020000031A DO 2020000031 A DO2020000031 A DO 2020000031A DO P2020000031 A DOP2020000031 A DO P2020000031A
Authority
DO
Dominican Republic
Prior art keywords
tablets
during storage
good stability
stability during
improved acceptance
Prior art date
Application number
DO2020000031A
Other languages
English (en)
Inventor
Kanikanti Venkata-Rangarao
Hamann Hans-Jürgen
Schulte Georg
Billian Patrick
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of DOP2020000031A publication Critical patent/DOP2020000031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a comprimidos para animales que tienen una aceptación mejorada y buena estabilidad durante el almacenamiento.
DO2020000031A 2012-12-19 2020-02-10 Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento DOP2020000031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198101 2012-12-19
PCT/EP2013/076878 WO2014095845A1 (de) 2012-12-19 2013-12-17 Tabletten mit verbesserter akzeptanz und guter lagerstabilität

Publications (1)

Publication Number Publication Date
DOP2020000031A true DOP2020000031A (es) 2020-02-28

Family

ID=47458712

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2015000150A DOP2015000150A (es) 2012-12-19 2015-06-15 Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento
DO2020000031A DOP2020000031A (es) 2012-12-19 2020-02-10 Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2015000150A DOP2015000150A (es) 2012-12-19 2015-06-15 Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento

Country Status (24)

Country Link
US (2) US10543170B2 (es)
EP (1) EP2934490B1 (es)
JP (1) JP6393274B2 (es)
KR (1) KR102253847B1 (es)
CN (1) CN105025885B (es)
AU (1) AU2013361760B2 (es)
CA (1) CA2895254C (es)
CL (1) CL2015001685A1 (es)
CR (1) CR20150321A (es)
DO (2) DOP2015000150A (es)
EC (1) ECSP15026203A (es)
ES (1) ES2848394T3 (es)
HK (1) HK1216856A1 (es)
IL (1) IL239297B (es)
MX (1) MX375182B (es)
MY (1) MY175703A (es)
NZ (1) NZ708741A (es)
PH (1) PH12015501390A1 (es)
PT (1) PT2934490T (es)
RU (1) RU2693005C2 (es)
SV (1) SV2015004997A (es)
UA (1) UA118748C2 (es)
WO (1) WO2014095845A1 (es)
ZA (1) ZA201505170B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ708741A (en) * 2012-12-19 2019-11-29 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
CN106580896A (zh) * 2016-12-07 2017-04-26 成都乾坤动物药业股份有限公司 一种非班太尔分散片及其制备方法
CN110022862B (zh) 2016-12-09 2022-05-24 拜耳动物保健有限责任公司 药物制剂及其制造方法
EP4487846A3 (en) * 2018-09-05 2025-03-19 Zoetis Services LLC Palatable antiparasitic formulations
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
DE3705227A1 (de) 1987-02-19 1988-09-01 Bayer Ag Anthelminthische wirkstoffkombinationen
FR2715803B3 (fr) 1994-02-04 1996-05-10 Attali Jean Claude Leurre et procédé facilitant la prise de médicaments par certains animaux et en particulier par les chiens.
DE670160T1 (de) 1994-03-01 1996-03-14 Gergely, Gerhard, Dr., Wien Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
DE19520275A1 (de) 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20040180034A1 (en) 2003-03-10 2004-09-16 Lyn Hughes Anthelmintic resinates and a method for their preparation
DE10328666A1 (de) 2003-06-26 2005-01-13 Bayer Healthcare Ag Tabletten enthaltend Geschmacks-und/oder Aromastoffe
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
GB2407498B (en) 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US7348027B2 (en) * 2005-04-08 2008-03-25 Bayer Healthcare Llc Taste masked veterinary formulation
JP2007269716A (ja) * 2006-03-31 2007-10-18 Sato Pharmaceutical Co Ltd 塩酸セチリジン含有粒子
DE102008022520A1 (de) 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2010132286A1 (en) 2009-05-12 2010-11-18 Wyeth Llc Orally administered tablet formulation of an antianxiolytic compound
GB2475701B (en) * 2009-11-26 2011-10-19 Michael Hilary Burke A process for the preparation of an orally administered anthelmintic unit dose tablet
ES2806256T3 (es) 2010-10-12 2021-02-17 Bayer Ip Gmbh Productos masticables blandos no basados en almidón
LT2811998T (lt) * 2012-02-06 2019-02-25 Merial, Inc. Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sistemiškai veikiančius aktyviuosius agentus, būdai ir jų panaudojimas
NZ708741A (en) * 2012-12-19 2019-11-29 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
GB201413832D0 (en) * 2014-08-05 2014-09-17 Tate & Lyle Ingredients Starch compositions useful for thickening aqueous liquids

Also Published As

Publication number Publication date
UA118748C2 (uk) 2019-03-11
MX375182B (es) 2025-03-06
ES2848394T3 (es) 2021-08-09
HK1216856A1 (zh) 2016-12-09
MX2015007640A (es) 2015-09-23
US11147764B2 (en) 2021-10-19
DOP2015000150A (es) 2015-07-15
IL239297A0 (en) 2015-07-30
CA2895254A1 (en) 2014-06-26
WO2014095845A1 (de) 2014-06-26
EP2934490B1 (de) 2020-08-12
JP2016503767A (ja) 2016-02-08
CR20150321A (es) 2015-07-29
EP2934490A1 (de) 2015-10-28
KR102253847B1 (ko) 2021-05-21
AU2013361760A1 (en) 2015-07-09
SV2015004997A (es) 2017-05-12
US10543170B2 (en) 2020-01-28
CL2015001685A1 (es) 2015-10-23
MY175703A (en) 2020-07-06
CN105025885A (zh) 2015-11-04
KR20150094643A (ko) 2015-08-19
NZ708741A (en) 2019-11-29
AU2013361760B2 (en) 2018-07-05
IL239297B (en) 2021-10-31
JP6393274B2 (ja) 2018-09-19
US20150342889A1 (en) 2015-12-03
CA2895254C (en) 2021-01-26
ECSP15026203A (es) 2016-01-29
RU2015129310A (ru) 2017-01-24
ZA201505170B (en) 2025-02-26
RU2693005C2 (ru) 2019-07-01
CN105025885B (zh) 2022-04-08
US20200113823A1 (en) 2020-04-16
PT2934490T (pt) 2020-12-15
PH12015501390A1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
DOP2020000031A (es) Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento
EP2621302A4 (en) Heel-end slip shoe
DK3702351T3 (da) Formulering omfattende en mek-inhibitor
PL2919766T3 (pl) Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
UY4230Q (es) Bocadillo retorcido para mascota
UY34970A (es) Una Plataforma Elevable para Espectáculos Acuáticos
BR112014009503A2 (pt) formulações antimicrobianas com ácido pelargônico
CO6990720A2 (es) Composiciones que comprenden galatos y galamidas
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
FR2989055B1 (fr) Cloison de pied milieu affaiblie en y et renforcee en z.
DK2934510T3 (da) Lfa-1-inhibitorformuleringer
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
CO7200262A2 (es) Nueva dosificación y formulación
PL2837672T3 (pl) Złożony środek zmniejszający palność. kompozycja żywicy i kształtowany wyrób
CL2015002389A1 (es) Composiciones herbicidas que contienen isoxabena y flufenaceto.
PL2984434T3 (pl) System magazynowania termochemicznego o zwiększonej wydajności przechowywania
FR2986542B1 (fr) Pieu d'ancrage
ES1078174Y (es) Plantilla para calzado
ITMC20130025A1 (it) Calzatura incorporante una zeppa e una suola.
UA25086S (uk) Диван «бранд»
TH1301005823B (th) องค์ประกอบฆ่าวัชพืชที่ประกอบรวมด้วยฟลาซาซัลฟูรอน และเมทไตรบูซิน
UA25085S (uk) Диван «сван»
ES1095431Y (es) "Sandalia"
CR20130420A (es) Antioxidante solido soluble en agua
UA25965S (uk) Каблук